Literature DB >> 27314967

Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification.

José Berciano1, María J Sedano2, Ana L Pelayo-Negro2, Antonio García3, Pedro Orizaola3, Elena Gallardo4, Miguel Lafarga5, María T Berciano5, Bart C Jacobs6.   

Abstract

Guillain-Barré syndrome (GBS) is an acute-onset, immune-mediated disorder of the peripheral nervous system. In early GBS, arbitrarily established up to 10 days of disease onset, patients could exhibit selective manifestations due to involvement of the proximal nerves, including nerve roots, spinal nerves and plexuses. Such manifestations are proximal weakness, inaugural nerve trunk pain, and atypical electrophysiological patterns, which may lead to delayed diagnosis. The aim of this paper was to analyze the nosology of early GBS reviewing electrophysiological, autopsy and imaging studies, both in acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor/motor-sensory axonal neuropathy (AMAN/AMSAN). Early electrophysiology showed either well-defined demyelinating or axonal patterns, or a non-diagnostic pattern with abnormal late responses; there may be attenuated M responses upon lumbar root stimulation as the only finding. Pathological changes predominated in proximal nerves, in some studies, most prominent at the sides where the spinal roots unite to form the spinal nerves; on very early GBS endoneurial inflammatory edema was the outstanding feature. In the far majority of cases, spinal magnetic resonance imaging showed contrast enhancement of cauda equina, selectively involving anterior roots in AMAN. Both in AIDP and AMAN/AMSAN, ultrasonography has demonstrated frequent enlargement of ventral rami of C5-C7 nerves with blurred boundaries, whereas sonograms of upper and lower extremity peripheral nerves exhibited variable and less frequent abnormalities. We provide new insights into the pathogenesis and classification of early GBS.

Entities:  

Keywords:  Acute motor axonal neuropathy; Acute motor-sensory axonal neuropathy; Axonal degeneration; Demyelination; Early Guillain–Barré syndrome; Electrophysiology; Endoneurial fluid pressure; Endoneurial inflammatory edema; Experimental allergic neuritis; Magnetic resonance imaging; Nerve trunk pain; Spinal nerve; Spinal roots; Ultrasonography

Mesh:

Year:  2016        PMID: 27314967     DOI: 10.1007/s00415-016-8204-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  88 in total

1.  A clinicopathological study of the Guillain-Barré syndrome. Nine cases and literature review.

Authors:  M Honavar; J K Tharakan; R A Hughes; S Leibowitz; J B Winer
Journal:  Brain       Date:  1991-06       Impact factor: 13.501

Review 2.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

3.  Early axonal Guillain-Barré syndrome with normal peripheral conduction: imaging evidence for changes in proximal nerve segments.

Authors:  José Berciano; Elena Gallardo; Pedro Orizaola; Enrique Marco de Lucas; Antonio García; Ana L Pelayo-Negro; María J Sedano
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-05-13       Impact factor: 10.154

4.  Factors contributing to delay in diagnosis of Guillain-Barré syndrome and impact on clinical outcome.

Authors:  Divyanshu Dubey; Marissa Kapotic; Matthew Freeman; Anshudha Sawhney; Julio C Rojas; Worthy Warnack; Steven Vernino
Journal:  Muscle Nerve       Date:  2015-08-08       Impact factor: 3.217

5.  Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies.

Authors:  S Kuwabara; K Ogawara; K Mizobuchi; M Koga; M Mori; T Hattori; N Yuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-02       Impact factor: 10.154

6.  The axon in Guillain-Barré syndrome: immune target or innocent bystander?

Authors:  H C Powell; R R Myers
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

7.  Pain due to peripheral nerve damage: an hypothesis.

Authors:  A K Asbury; H L Fields
Journal:  Neurology       Date:  1984-12       Impact factor: 9.910

Review 8.  Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update.

Authors:  Antonino Uncini; Satoshi Kuwabara
Journal:  Clin Neurophysiol       Date:  2012-04-04       Impact factor: 3.708

9.  An acute axonal form of Guillain-Barré polyneuropathy.

Authors:  T E Feasby; J J Gilbert; W F Brown; C F Bolton; A F Hahn; W F Koopman; D W Zochodne
Journal:  Brain       Date:  1986-12       Impact factor: 13.501

10.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

View more
  11 in total

1.  MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes.

Authors:  W Ludo van der Pol; H Stephan Goedee; Marieke H J van Rosmalen; Martijn Froeling; Stefano Mandija; Jeroen Hendrikse
Journal:  J Neurol       Date:  2022-01-06       Impact factor: 4.849

2.  A novel prognostic system based on clinical and laboratory parameters for childhood Guillain-Barre syndrome.

Authors:  Ishita Tiwari; Areesha Alam; Chandra Kanta; Sciddhartha Koonwar; Ravindra Kumar Garg; Shweta Pandey; Amita Jain; Rashmi Kumar
Journal:  Acta Neurol Belg       Date:  2022-06-26       Impact factor: 2.471

3.  Re-evaluating the accuracy of optimized electrodiagnostic criteria in very early Guillain-Barré syndrome: a sequential study.

Authors:  Velina Nedkova; Gerardo Gutiérrez-Gutiérrez; Francisco J Navacerrada-Barrero; José Berciano; Carlos Casasnovas
Journal:  Acta Neurol Belg       Date:  2021-02-18       Impact factor: 2.396

4.  Reversible conduction failure on the deep tendon reflex response recording in early Guillain-Barré syndrome.

Authors:  Antonio García; María J Sedano; Silvia Álvarez-Paradelo; José Berciano
Journal:  Clin Neurophysiol Pract       Date:  2018-11-03

Review 5.  Diagnosis and management of Guillain-Barré syndrome in ten steps.

Authors:  Sonja E Leonhard; Melissa R Mandarakas; Francisco A A Gondim; Kathleen Bateman; Maria L B Ferreira; David R Cornblath; Pieter A van Doorn; Mario E Dourado; Richard A C Hughes; Badrul Islam; Susumu Kusunoki; Carlos A Pardo; Ricardo Reisin; James J Sejvar; Nortina Shahrizaila; Cristiane Soares; Thirugnanam Umapathi; Yuzhong Wang; Eppie M Yiu; Hugh J Willison; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2019-09-20       Impact factor: 42.937

Review 6.  Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP.

Authors:  Luis Querol; Cinta Lleixà
Journal:  Neurotherapeutics       Date:  2021-09-21       Impact factor: 7.620

7.  Serum Folate Correlates with Severity of Guillain-Barré Syndrome and Predicts Disease Progression.

Authors:  Yang Gao; Hong-Liang Zhang; Meiying Xin; Dong Wang; Nannan Zheng; Shuang Wang; Jiancheng Xu; Ying Wang; Jie Zhu; Jiachun Feng
Journal:  Biomed Res Int       Date:  2018-06-14       Impact factor: 3.411

8.  Very early Guillain-Barré syndrome: A clinical-electrophysiological and ultrasonographic study.

Authors:  José Berciano; Pedro Orizaola; Elena Gallardo; Ana L Pelayo-Negro; Pascual Sánchez-Juan; Jon Infante; María J Sedano
Journal:  Clin Neurophysiol Pract       Date:  2019-11-30

9.  Spinal nerve pathology in Guillain-Barré syndrome associated with COVID-19 infection.

Authors:  José Berciano; Elena Gallardo
Journal:  Muscle Nerve       Date:  2020-08-11       Impact factor: 3.852

10.  Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases.

Authors:  Samir Abu-Rumeileh; Ahmed Abdelhak; Matteo Foschi; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2020-08-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.